Prior to joining Anaptys, he was an operating principal at Two River, where he co-founded and held interim senior leadership roles in 76Bio and IconoVir Bio. Previously, Ben led the Corporate Strategy function at Spark Therapeutics until its acquisition by Roche and was a member of the Healthcare Investment Banking Group at Credit Suisse. He earned a B.S. in Finance from the Wharton School of the University of Pennsylvania and a B.A. in International Studies from the University of Pennsylvania.